When tumor size reached ~100 mm3 volume, mice received 7.4 kBq of 225Ac-anti-CCR8 and a loading dose (10 mg/kg, 200 μg) of CTLA-4 immunotherapy. This evidence concerns the gene CTLA4 and neoplasm.